Focus: AilseBio is a newly founded (2024) UK-based biotechnology company focused on immuno-oncology vaccines spanning oncology, infectious diseases, and vaccine development. The company is in pre-clinical/early-stage discovery with no disclosed pipeline programs or approved products.
Profile data last refreshed 2d ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow AilseBio to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
No open positions listed yet.
Help build intelligence for AilseBio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from AilseBio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo